1 October 2012Copyright
Under scrutiny: IP in India
Perhaps most notable in a year of notable developments was the compulsory licence granted to local company Natco allowing it the right to sell Bayer’s Nexavar cancer drug at a lower cost in India.
Perhaps most notable in a year of notable developments was the compulsory licence granted to local company Natco allowing it the right to sell Bayer’s Nexavar cancer drug at a lower cost in India.
